Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ZNTL
SELLZentalis Pharmaceuticals, Inc. · Healthcare · United States · $308M · Avg Vol: $6M/d
28
StockRankGet insider-trade alerts
Q
26
V
31
M
60
P/E (TTM)
—
ROE
-51.9%
D/E
0.2x
Dividend %
—
Loading 1Y...
PRICE (1Y)+20.3%
SMA 50SMA 200
Close
$4.51
RSI (14)
44.7
52W High
$6.95
From 52W High
0.6%
SCORE BREAKDOWN
Quality
26
ROIC
-57.5%13.4
ROE
-51.9%17.9
GP/Assets
—N/A
Op. Margin
0.0%41.3
FCF/Assets
-28.2%12.4
Piotroski
111.4
Int. Cover
—N/A
D/E Ratio
0.21x48.8
Current Ratio
6.19x76.7
Value
31
P/E (TTM)
—N/A
EV/EBITDA
-1.0x25.0
P/FCF
—N/A
P/B
1.7x66.9
P/S
—N/A
Div Yield
—N/A
Momentum
60
52W High %
65%46.3
RS 6M
46%93.0
SMA 50/200
1.45x97.6
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+12%29.4
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$308M
P/E (Forward)
-2.8x
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ZNTL are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ZNTL | Zentalis Pharmaceuticals, Inc.(you) | $308M | 28 | SELL |
| VNDA | Vanda Pharmaceuticals Inc. | $312M | 26 | SELL |
| PALI | Palisade Bio, Inc. | $339M | 29 | SELL |
| FATE | Fate Therapeutics, Inc. | $281M | 26 | SELL |
| OABI | OmniAb, Inc. | $294M | 32 | SELL |
| SABS | SAB Biotherapeutics, Inc. | $268M | 27 | SELL |
| TENX | Tenax Therapeutics, Inc. | $385M | 28 | SELL |
| IPSC | Century Therapeutics, Inc. | $381M | 28 | SELL |
| PRLD | Prelude Therapeutics Incorporated | $305M | 24 | SELL |
| AVIR | Atea Pharmaceuticals, Inc. | $379M | 29 | SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.5%